ReviewDiscover nano2026
Nanomaterial toxicity and risk assessment integrating functionalization strategies advanced in vitro models and regulatory perspectives.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanomaterials have gained huge importance in various fields, such as healthcare, electronics, and environmental management, due to their unique characteristics. However, the potent toxicity is a big concern regarding their utility. Toxicological assessment becomes an important step to ensure their safe applications. The significant hazards of nanomaterials have risen from their shape, size, charge, and makeup, which leads to genetic damage, cellular uptake, and internalization with oxidative stress (OS) and harm to specific organs. This review focuses on toxicity profiles and their possible interactions with cellular organelles leading to apoptosis (Apop) and long-term bioaccumulation.Size, surface area, and dissolving capability may affect the toxicity of nanomaterials. Different measures such as encapsulation methods, increasing surface area, and enhancing biodegradability are being considered to reduce toxicity from innovative nanomaterials. Knowledge gaps encompass uneven toxicity evaluations, inadequate chronic exposure data, and insufficient attention to individualized reactions. The integration of standardized models, computational predictions, mechanistic investigations, and regulatory compliance is crucial for the safer design of nanomaterials. The review highlights toxicological issues caused by nanomaterials such as nanoformulation, quantum dots, and nanoparticles. It also directs future strategies in nanotoxicology, highlighting increasing assessment models, strategies, and collaborative research efforts. Bringing together regulatory and research efforts in the context of nanomaterials is important for ensuring the safe application of nanomaterials across pharmacy and other industries. This review offers a comprehensive viewpoint connecting physicochemical factors, sophisticated in vitro models, and developing regulatory frameworks, emphasizing emerging trends including microphysiological systems and animal-free risk assessment methodologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.